Skip to main content
SpringerLink
Log in

Prevention of delayed emesis induced by moderately emetogenic chemotherapy in patients with acute emesis

A pilot study with ACTH-depot plus tropisetron

  • Original Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The rates of delayed nausea and vomiting by moderately emetogenic chemotherapy in patients with previous experience of acute emesis are usually quite high. This is a pilot study aiming to evaluate the safety of a new antiemetic schedule to prevent delayed emesis in this subset of patients.

During 5 consecutive cycles of moderately emetogenic chemotherapy, we evaluated 50 patients (15 males) who experienced acute emesis in the first cycle of treatment. The regimen for prevention of delayed emesis consisted of daily tropisetron (5 mg orally from d 2 to d 6 of each chemotherapeutic cycle) associated to ACTH-Depot (1 mg intramuscularly 24 and 68 h after the initiation of chemotherapy).

In 77% of chemotherapy cycles, there was a total elimination of nausea and vomiting, whereas in the remaining 23% of cycles, there was a major response defined as ≤ 2 vomiting episodes per cycle or nausea grade 1 according to the WHO. The efficacy of the antiemetic regimen persisted during the entire treatment program without the appearance of toxic effects.

The proposed antiemetic regimen is highly active in preventing delayed nausea and vomiting episodes in patients receiving moderately emetogenic chemotherapy. Moreover, no toxic effects were observed. These promising results require confirmation by a randomized trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kris, M.G., Roila, F., De Mulder, P.H., et al. (1998). Delayed emesis following anticancer chemotherapy. Support Care Cancer 6(3):228–232.

    Article  PubMed  CAS  Google Scholar 

  2. Ballatori, E., Roila, F., De Angelis, V., et al. (1997). Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts’ opinions. Multinational Association of Supportive Care in Cancer. Support Care Cancer 5(4):269–273.

    Article  PubMed  CAS  Google Scholar 

  3. The Italian Group for Antiemetic Research. (1997). Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? Ann. Oncol. 8(6):561–567.

    Article  Google Scholar 

  4. Yalcin, S., Tekuzman, G., Baltali, E., et al. (1999). Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study. Am. J. Clin. Oncol. 22(1):94–96.

    Article  PubMed  CAS  Google Scholar 

  5. Roila, F., and Del Favero, A. (1997). Antiemetics revisited. Curr. Opin. Oncol. 9(4):321–326.

    Article  PubMed  CAS  Google Scholar 

  6. Campora, E., Giudici, S., Merlini, I., et al. (1994). Ondansetron and dexamethasone versus standard combination antiemetic therapy: a randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance at subsequent courses. Am. J. Clin. Oncol.: Cancer Clin. Trials 17(6):522–526.

    CAS  Google Scholar 

  7. Pater, J.L., Lofters, W.S., Zee, B., et al. (1997). The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in the patients receiving moderately emetogenic chemotherapy. Ann. Oncol. 8(2):181–185.

    Article  PubMed  CAS  Google Scholar 

  8. Lofters, W.S., Pater, J.L., Zee, B., et al. (1997). Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J. Clin. Oncol. 15(8):2966–2973.

    PubMed  CAS  Google Scholar 

  9. Ioannidis, J.P., Hesketh, P.J., and Lau, J. (2000). Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J. Clin. Oncol. 18(19):3409–3422.

    PubMed  CAS  Google Scholar 

  10. Perez, E.A. (1999). 5-HT3 antiemetic therapy for patients with breast cancer. Breast Cancer Res. Treat. 57(2):207–214.

    Article  PubMed  CAS  Google Scholar 

  11. Antiemetic Subcommission of the Multinational Association of Supportive Care in Cancer (MASCC). (1998). Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Ann. Oncol. 9(8):811–819.

    Article  Google Scholar 

  12. Gregory, R.E. and Ettinger, D.S. (1998). 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 55(2):173–189.

    Article  PubMed  CAS  Google Scholar 

  13. Kaizer, L., Warr, D., Hoskins, P., et al. (1994). Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 12(5):1050–1057.

    PubMed  CAS  Google Scholar 

  14. Koo, W.H. and Ang, P.T. (1996). Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann. Oncol. 7(1):71–74.

    PubMed  CAS  Google Scholar 

  15. The Italian Group for Antiemetic Research. (1995). Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N. Engl. J. Med. 332(1):1–5.

    Article  Google Scholar 

  16. The Italian Group for Antiemetic Research. (2000). Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N. Engl. J. Med. 342(21):1554–1559.

    Article  Google Scholar 

  17. Colbert, N., Izrael, V., Lotz, J.P., et al. (1983). Adrenocorticotropic hormone in the prevention of cisplatininduced nausea and vomiting. J. Clin. Oncol. 1(10):635–639.

    PubMed  CAS  Google Scholar 

  18. Passalacqua, R., Cocconi, G., Bella, M., et al. (1992). Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: Comparison of placebo vs adrenocorticotropic hormone (ACTH). Ann. Oncol. 3(6):481–485.

    PubMed  CAS  Google Scholar 

  19. Passalacqua, R., Cocconi, G., Caminiti, C., et al. (1997). Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cis-platin in adult patients with cancer. J. Clin. Oncol. 15(6):2467–2473.

    PubMed  CAS  Google Scholar 

  20. Dunn, A.J. and Gipsen, W.H. (1997). How ACTH acts on the brain. Biobehav. Rev. 1:15–23.

    Article  Google Scholar 

  21. Karim, F., Roerig, S.C. and Saphier, D. (1996). Role of 5-hydroxytryptamine3 (5-HT3) antagonists in the prevention of emesis caused by anticancer therapy. Biochem. Pharmacol. 52(5):685–685.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Campus Bio-Medico University, Rome, Italy

    D. Santini, B. Vincenzi, C. Fossati, R. M. D’Angelillo, G. Patti, G. Avvisati & G. Tonini

  2. Division of Oncology, “La Sapienza” University, Rome, Italy

    V. Bianco

Authors
  1. D. Santini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Vincenzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Fossati
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. M. D’Angelillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Patti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. Bianco
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Avvisati
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Tonini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Tonini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Santini, D., Vincenzi, B., Fossati, C. et al. Prevention of delayed emesis induced by moderately emetogenic chemotherapy in patients with acute emesis. Med Oncol 18, 131–135 (2001). https://doi.org/10.1385/MO:18:2:131

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MO:18:2:131

Key Words

Search

Navigation